WO2012060607A3 - 혈전 용해용 조성물 및 이를 포함하는 혈관 협착 또는 폐색성 질환의 치료용 약제학적 조성물 - Google Patents

혈전 용해용 조성물 및 이를 포함하는 혈관 협착 또는 폐색성 질환의 치료용 약제학적 조성물 Download PDF

Info

Publication number
WO2012060607A3
WO2012060607A3 PCT/KR2011/008248 KR2011008248W WO2012060607A3 WO 2012060607 A3 WO2012060607 A3 WO 2012060607A3 KR 2011008248 W KR2011008248 W KR 2011008248W WO 2012060607 A3 WO2012060607 A3 WO 2012060607A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
composition
vascular diseases
occlusive vascular
pharmaceutical composition
Prior art date
Application number
PCT/KR2011/008248
Other languages
English (en)
French (fr)
Other versions
WO2012060607A2 (ko
Inventor
허지회
권일
김영대
홍성유
Original Assignee
연세대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 연세대학교 산학협력단 filed Critical 연세대학교 산학협력단
Priority to JP2013537603A priority Critical patent/JP5894176B2/ja
Priority to US13/882,792 priority patent/US9982021B2/en
Priority to CN201180052931.0A priority patent/CN103327996B/zh
Priority to EP11838212.6A priority patent/EP2636412A4/en
Publication of WO2012060607A2 publication Critical patent/WO2012060607A2/ko
Publication of WO2012060607A3 publication Critical patent/WO2012060607A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

본 발명은 Arg-Gly-Asp 모티프(motif)를 포함하는 펩타이드를 포함하는 혈전 용해용 조성물, 이를 포함하는 혈관 협착 또는 폐색성 질환의 치료용 약제학적 조성물, 그리고 이를 투여하는 단계를 포함하는 혈전 용해방법 및 혈관 협착 또는 폐색성 질환의 치료방법에 관한 것이다. 본 발명의 조성물 및 방법은 기존의 플라스미노겐 활성화 원리가 아닌 혈소판 표면 GPIIb-IIIa와 같은 혈전 내 인테그린 타겟 원리를 채택하여 이미 생성된 혈전을 효과적으로 분해하는 장점이 있다. 또한, 본 발명의 조성물 및 방법은 관통 후 재협착도 일으키지 않고, 미세혈관까지 효과적으로 개방시키며 신경보호 효능이 있다.
PCT/KR2011/008248 2010-11-01 2011-11-01 혈전 용해용 조성물 및 이를 포함하는 혈관 협착 또는 폐색성 질환의 치료용 약제학적 조성물 WO2012060607A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2013537603A JP5894176B2 (ja) 2010-11-01 2011-11-01 血栓溶解用組成物及びこれを含む血管狭窄又は閉塞性疾患の治療用医薬組成物
US13/882,792 US9982021B2 (en) 2010-11-01 2011-11-01 Composition for dissolving thrombi, and a pharmaceutical composition for treating stenotic or occlusive vascular diseases which comprises the same
CN201180052931.0A CN103327996B (zh) 2010-11-01 2011-11-01 血栓溶解用组合物及包含其的血管狭窄或闭塞性疾病的治疗用药剂学组合物
EP11838212.6A EP2636412A4 (en) 2010-11-01 2011-11-01 COMPOSITION FOR RESOLVING THROMBES AND PHARMACEUTICAL COMPOSITION CONTAINING THIS COMPOSITION FOR THE TREATMENT OF STENOTIC OR SEAL DISORDERS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0107760 2010-11-01
KR20100107760 2010-11-01

Publications (2)

Publication Number Publication Date
WO2012060607A2 WO2012060607A2 (ko) 2012-05-10
WO2012060607A3 true WO2012060607A3 (ko) 2012-08-23

Family

ID=46024939

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/008248 WO2012060607A2 (ko) 2010-11-01 2011-11-01 혈전 용해용 조성물 및 이를 포함하는 혈관 협착 또는 폐색성 질환의 치료용 약제학적 조성물

Country Status (7)

Country Link
US (1) US9982021B2 (ko)
EP (2) EP2636412A4 (ko)
JP (1) JP5894176B2 (ko)
KR (1) KR101463181B1 (ko)
CN (1) CN103327996B (ko)
ES (1) ES2679400T3 (ko)
WO (1) WO2012060607A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2687992T3 (es) 2013-07-30 2018-10-30 Industry-Academic Cooperation Foundation, Yonsei University Proteína de fusión saxatilina-Fc y utilización de la misma
KR101724129B1 (ko) * 2014-03-28 2017-04-10 연세대학교 산학협력단 Rgd 모티프를 포함하는 펩타이드 또는 단백질을 포함하는 신경염증 예방, 억제 또는 치료용 조성물
KR102055390B1 (ko) * 2017-01-06 2019-12-12 경북대학교 산학협력단 혈전-표적성 펩타이드, 페리틴 단편 및 혈전 용해성 펩타이드를 포함하는 융합 펩타이드 및 이의 용도
CN110724678B (zh) * 2019-10-21 2022-04-22 陕西师范大学 中介蝮蛇毒纤溶酶及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498601A (en) * 1992-07-09 1996-03-12 Nippon Steel Corporation Platelet aggregation-inhibiting peptides
KR100458362B1 (ko) * 2002-03-26 2004-11-26 김두식 한국산 칠점사로부터 유래된 단백질 및 그의 제조방법
KR100835736B1 (ko) * 2003-07-25 2008-06-09 (주)바이오버드 디스인테그린을 포함하는 항혈전제

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6470590A (en) * 1989-10-23 1991-04-26 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US5643872A (en) * 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
WO1991011458A1 (en) * 1990-02-02 1991-08-08 Genentech, Inc. CYCLIC PEPTIDES CONTAINING Arg-Gly-Asp FLANKED BY PROLINE
JPH05112454A (ja) * 1991-10-18 1993-05-07 Nissan Chem Ind Ltd 抗血小板剤
US6184206B1 (en) * 1997-09-03 2001-02-06 The Burnham Institute Integrin ligand dissociators
JPH11279174A (ja) * 1998-03-27 1999-10-12 Meiji Seika Kaisha Ltd 血小板凝集阻害作用を有するベンジルアルコール誘導体
CN1184313C (zh) * 2000-07-26 2005-01-12 郑光会 衍生自黑眉蝮蛇的新型蛋白以及制备该蛋白的方法
JP2003048889A (ja) * 2001-08-01 2003-02-21 Ajinomoto Co Inc 新規核酸系化合物
EP1740203A4 (en) * 2004-03-31 2008-02-13 Eyegene Inc POLYPEPTIDE INDUCING THE ANGIOPOIETINE SECRETION
KR101049505B1 (ko) * 2006-01-19 2011-07-15 아이진 주식회사 펩타이드를 유효성분으로 하는 혈관 관련 질환 치료제조성물
US7943728B2 (en) * 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
KR20090036908A (ko) * 2007-10-10 2009-04-15 연세대학교 산학협력단 뱀독 유래의 디스인테그린인 삭사틸린을 포함하는동맥경화증 예방 또는 치료용 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498601A (en) * 1992-07-09 1996-03-12 Nippon Steel Corporation Platelet aggregation-inhibiting peptides
KR100458362B1 (ko) * 2002-03-26 2004-11-26 김두식 한국산 칠점사로부터 유래된 단백질 및 그의 제조방법
KR100835736B1 (ko) * 2003-07-25 2008-06-09 (주)바이오버드 디스인테그린을 포함하는 항혈전제

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EDWIN A. CLARK ET AL.: "Structurally Distinct Disintegrins Contortrostatin and Multisquamatin Differentially Regulate Platelet Tyrosine Phosphorylation", J. BIOL. CHEM., vol. 269, no. 35, 1994, pages 21940 - 21943, XP055115426 *
See also references of EP2636412A4 *

Also Published As

Publication number Publication date
EP2636412A4 (en) 2014-06-25
KR101463181B1 (ko) 2014-11-27
CN103327996B (zh) 2016-06-15
JP2013542952A (ja) 2013-11-28
ES2679400T3 (es) 2018-08-27
US20130316951A1 (en) 2013-11-28
EP2636412A2 (en) 2013-09-11
CN103327996A (zh) 2013-09-25
WO2012060607A2 (ko) 2012-05-10
EP2845601A1 (en) 2015-03-11
EP2845601B1 (en) 2018-04-25
KR20120061036A (ko) 2012-06-12
JP5894176B2 (ja) 2016-03-23
US9982021B2 (en) 2018-05-29

Similar Documents

Publication Publication Date Title
WO2012156537A3 (en) Lysine demethylase inhibitors such as cyclylcylopropamine derivatives for use in the treatment of thrombosis and cardiovascular diseases
WO2010032875A3 (en) Heterocyclic carboxamide compounds
WO2013009754A3 (en) Enhanced antimicrobial peracid compositions and methods of use at reduced temperatures in aseptic cleaning
CL2013001340A1 (es) Compuestos derivados de isoindol-amida, pirrolo-piridin-amida y pirrolo-pirimimidin-amida, inhibidores de nampt y rock; composicion farmaceutica; y metodo para tratar hiperetension, insuficiencia cardiaca cronica, aterosclerosis, asma, enfermedad de alzheimer, enfermedad de parkinson y glaucoma, entre otras enfermedades.
WO2010108074A3 (en) Inhibitors of pi3 kinase
WO2012060607A3 (ko) 혈전 용해용 조성물 및 이를 포함하는 혈관 협착 또는 폐색성 질환의 치료용 약제학적 조성물
GB201304501D0 (en) Liquid pharmaceutical compositions
WO2011006143A3 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases, such as e.g. malaria
WO2013009527A3 (en) Factor ixa inhibitors
MY156601A (en) Spiro-indole derivatives for the treatment of parasitic diseases
WO2012054535A3 (en) Compounds, compositions and methods useful for cholesterol mobilisation
WO2013034855A3 (fr) Association de carraghénane et de c-glycoside et leurs utilisations
MY146407A (en) A medicament comprising a carbostyril derivative and donepezil for treating alzheimer's disease
CA2866232A1 (en) Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
WO2013080217A3 (en) Crystalline forms of carbazitaxel and process for preparation thereof
WO2012050393A3 (ko) 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도
WO2012010978A3 (en) A method of treating alzheimer's disease
EA201290603A1 (ru) Способ лечения
WO2012053009A3 (en) Pharmaceutical compositions comprising nano size droplets of skin whitening agents
WO2014130752A3 (en) Bicyclic compounds
PH12014501425A1 (en) Pharmaceutical preparation comprising brexpiprazole and substituted beta-cyclodextrin
WO2012017448A3 (en) Salts of lapatinib
WO2007097888A3 (en) Fluoroquinolone carboxylic acid salt compositions
WO2011090932A3 (en) A method of treating sinusitis, including chronic sinusitis
WO2010047819A8 (en) Hydroxyethylamino sulfonamide derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11838212

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013537603

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13882792

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2011838212

Country of ref document: EP